Dr Nathan Palpant

 - Chief Investigator

Research focus: Mechanisms underlying mesoderm cell lineage decisions using human pluripotent stem cells, genomics, genome engineering, and bioengineering

Dr Palpant received his B.S. in Biology from Whitworth University, USA. He then completed his PhD at the University of Michigan working on gene therapy of myofilament proteins for treatment of heart failure. Major findings from his work showed that a single amino acid substitution of alanine to histidine in the switch arm of cardiac troponin I was sufficient to protect hearts against severe acidosis as it occurs in the context of ischemic injury.

Dr Palpant then went on to work at the University of Washington where he studied cell lineage decisions from pluripotency. His studies revealed a molecular switch that could convert cells back and forth between the cardiac and endothelial lineages. He has also made strides in understand mechanisms of how cells give rise to the cardiovascular lineage using human pluripotent stem cells, genome engineering, bioengineering, and sequencing of chromatin modifications during differentiation.

In 2015, Dr Palpant commenced as a Group Leader at UQ's Institute for Molecular Bioscience (IMB), where he leads a research team studying the mechanisms underlying cell fate decisions in cardiovascular development.